Previous close | 0.2000 |
Open | 0.2000 |
Bid | 0.0500 |
Ask | 0.4000 |
Strike | 20.00 |
Expiry date | 2024-05-17 |
Day's range | 0.2000 - 0.2000 |
Contract range | N/A |
Volume | |
Open interest | 2 |
Despite Net Loss, Relay Therapeutics Reports Significant Revenue Growth and Robust Pipeline Progress
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 11.43% and 2,905.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second half of 2026CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2024 financial results and corporate highlights. “We have started 2024 with a focus